Asieris Pharmaceuticals (stock code: 688176.SH), a China-based global biopharma company, announced on Wednesday that it has named Dr Badrinath Konety as an advisor to the company's Scientific Advisory Board.

Dr Konety has over 30 years of clinical research and medical practice experience in the field of genitourinary oncology. Presently, he is the president of Allina Health Cancer Institute and chief system research officer and also a professor in the Department of Urology, Rush Medical College. He has held the position of professor and dougherty family chair in Uro-Oncology, and chairman, Department of Urology, University of Minnesota. He has served as CEO for University of Minnesota Physicians and Dean of Rush Medical College. He has held various leading positions and offices in professional organisations such as the presidents of Society of Academic Urologists and Societe Internationale d'Urologie.

Dr Kevin Pan, Asieris founder and CEO, said, 'We are honoured to have Dr Konety in our Scientific Advisory Board. With his profound expertise in the global genitourinary filed, we are confident that Dr. Konety will play a critical role in helping Asieris define and optimise growth objectives and strategies to accelerate its innovation ambitions to become a global specialty biopharmaceutical company.'